Company Encyclopedia
View More
name
Dr Reddys Laboratories
RDY.US
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
4.514 T
RDY.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking13/184
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE17.66%A
    • Profit Margin17.13%A
    • Gross Margin54.67%B
  • Growth ScoreB
    • Revenue YoY10.31%B
    • Net Profit YoY6.27%C
    • Total Assets YoY9.77%B
    • Net Assets YoY10.48%B
  • Cash ScoreB
    • Cash Flow Margin583.67%C
    • OCF YoY10.31%B
  • Operating ScoreB
    • Turnover0.68B
  • Debt ScoreB
    • Gearing Ratio33.20%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Dr. Reddy’s Laboratories Allots Equity Shares Under ESOP

    Dr. Reddy’s Laboratories announced the allotment of 7,430 equity shares to employees under its ESOP on November 13, 2025, reflecting its commitment to employee engagement and retention. The latest analyst rating for RDY stock is Hold with a $14.50 price target. The company, based in Hyderabad, India, is known for producing generic medications and is listed on major stock exchanges. Its current market cap is $11.57B.

    Tip Ranks·
    US
    RDY
    +0.07%
    Tip Ranks·
    US
    RDY
    +0.07%

    Dr. Reddy’s Releases Q3 2025 Earnings Call Recordings

    Dr. Reddy’s Laboratories announced the availability of audio recordings from their Q3 2025 earnings call, held on October 24, 2025. This initiative reflects the company's commitment to transparency and regulatory compliance, offering stakeholders insights into financial performance and strategy. The latest analyst rating for RDY stock is a Buy with a $16.00 price target. Spark's AI Analyst rates RDY as Outperform, noting strong financial performance and a balanced valuation, despite mixed technical signals. The company, based in Hyderabad, India, specializes in generic medications and has a market cap of $12.2B.

    Tip Ranks·
    US
    RDY
    +0.07%
    Tip Ranks·
    US
    RDY
    +0.07%

    Dr. Reddy’s Laboratories Releases Q2 2025 Financial Results

    Dr. Reddy’s Laboratories (RDY) announced its Q2 2025 financial results on October 25, 2025, complying with SEBI regulations. The latest analyst rating for RDY is a Buy with a $16.00 price target. Spark’s AI Analyst rates RDY as Outperform, citing strong financial performance and a solid balance sheet. Technical analysis shows mixed signals, with short-term bullish momentum but potential bearish trends. The company, based in Hyderabad, India, focuses on generic medications and has a market cap of $12.2B.

    Tip Ranks·
    US
    RDY
    +0.07%
    Tip Ranks·
    US
    RDY
    +0.07%

    Dr. Reddy’s Laboratories Releases Q2 FY2026 Financial Results

    Dr. Reddy’s Laboratories (RDY) announced its Q2 FY2026 financial results on October 24, 2025, during a board meeting. The results comply with International Financial Reporting Standards and Indian Accounting Standards, providing insights into the company's financial health. Analysts rate RDY stock as a Buy with a $16.00 price target. Spark's AI Analyst rates RDY as Outperform, highlighting strong financial performance and a balanced valuation. The company faces growth opportunities and challenges in the U.S. generics market. Dr. Reddy’s Laboratories is a leading pharmaceutical company based in Hyderabad, India, focusing on affordable medications.

    Tip Ranks·
    US
    RDY
    +0.07%
    Tip Ranks·
    US
    RDY
    +0.07%

    Dr. Reddy’s Laboratories Reports Stable Q3 2025 Financials

    Dr. Reddy’s Laboratories (RDY) reported stable Q3 2025 financials, confirming no material changes to its interim statements. The company remains focused on expanding its generic medicines despite challenges. Ernst & Young's review supports the reliability of the financial data. Analysts rate RDY stock as a Buy with a $16.00 target, reflecting strong performance and balanced valuation. Technical analysis shows mixed signals, with short-term bullish momentum. The company, based in Hyderabad, India, specializes in generic medicines and has a market cap of $12.25B.

    Tip Ranks·
    US
    RDY
    +0.07%
    Tip Ranks·
    US
    RDY
    +0.07%
    © 2025 Longbridge｜Disclaimer